Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00764322 · ClinicalTrials.gov registry record · Phase 2
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 501
- Enrollment target
NCT00764322 is a Phase 2 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 501 participants.
The verdict
NCT00764322, a Phase 2 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 501 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about differences in DNA and predict how well patients will respond to treatment and plan better treatment. PURPOSE: This clinical trial is studying blood samples from women with breast cancer or ductal carcinoma in situ who are receiving tamoxifen.
Interventions
- GENETIC gene expression analysis
- OTHER questionnaire administration
- PROCEDURE quality-of-life assessment
- OTHER pharmacogenomic studies
- DRUG tamoxifen citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2008-06-18 |
| Est. Completion | 2011-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00764322
The ClinicalTrials.gov registry entry for NCT00764322 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00764322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00764322 about?
NCT00764322 is a clinical study titled "Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen". RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about differences in DNA and predict how well patients will respond to treatment and plan better treatment. PURPOSE: This clinical trial is studying blood samples from women with breast canc...
What is the current status of trial NCT00764322?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 501 participants. The study started on 2008-06-18. Estimated completion is 2011-07-01.
What interventions are being tested in trial NCT00764322?
The interventions under investigation include: gene expression analysis (GENETIC), questionnaire administration (OTHER), quality-of-life assessment (PROCEDURE), pharmacogenomic studies (OTHER), tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT00764322?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.